0001654954-21-010086.txt : 20210914 0001654954-21-010086.hdr.sgml : 20210914 20210914172754 ACCESSION NUMBER: 0001654954-21-010086 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210914 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210914 DATE AS OF CHANGE: 20210914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharma-Bio Serv, Inc. CENTRAL INDEX KEY: 0001304161 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 200653570 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50956 FILM NUMBER: 211253281 BUSINESS ADDRESS: STREET 1: INDUSTRIAL ZONE STREET 1 STREET 2: LOT 14 CITY: DORADO STATE: PR ZIP: 00646 BUSINESS PHONE: 787-278-2709 MAIL ADDRESS: STREET 1: INDUSTRIAL ZONE STREET 1 STREET 2: LOT 14 CITY: DORADO STATE: PR ZIP: 00646 FORMER COMPANY: FORMER CONFORMED NAME: LAWRENCE CONSULTING GROUP INC DATE OF NAME CHANGE: 20040923 8-K 1 pbsv_8k.htm PRIMARY DOCUMENT pbsv_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): September 14, 2021

 

Pharma-Bio Serv, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

0-50956

 

20-0653570

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

6 Road 696, Dorado, Puerto Rico

 

00646

(Address of Principal Executive Offices)

 

(Zip Code)

 

(787) 278-2709

(Registrant’s Telephone Number, Including Area Code)

 

__________________________________________________

(Former Name or Former Address, if Changed Since Last Report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

 

 

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b2 of the Securities Exchange Act of 1934 (17 CFR §240.12b2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

Item 2.02 Results of Operations and Financial Condition

 

On September 14, 2021, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended July 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this report

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release, dated September 14, 2021

 

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PHARMA-BIO SERV, INC.

 

 

 

 

 

Date: September 14, 2021

By:

/s/ Pedro J. Lasanta

 

 

 

Pedro J. Lasanta

 

 

 

Chief Financial Officer, Vice President

Finance and Administration and Secretary

 

 

 

3

 

EX-99.1 2 pbsv_ex991.htm PRESS RELEASE pbsv_ex991.htm

EXHIBIT 99.1

 

Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2021

 

DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced revenues for the three and nine months ended July 31, 2021 were approximately $4,988,000 and $14,518,000, respectively, a decrease of approximately $1,290,000 and $2,021,000, respectively, when compared to the same periods last year.

 

Net income for the three and nine months ended July 31, 2021 was approximately $2,275,000 and $2,783,000, an increase of approximately $1,583,000 and $876,000 when compared to the same periods last year, respectively. Net income for the July 31, 2021 reported periods is inclusive of $1,956,000 in PPP loan forgiveness.

 

“We are focusing our efforts on pursuing projects within the continental US, as well as in Europe and Latin America. The launch of our Regulatory and Compliance Advisory Board last quarter was a milestone in the Company’s path for future success. Additionally, the Company is focused on its M&A strategy and ensuring that our organization is structured to quickly capitalize on non-organic growth opportunities, allowing us to continue to provide best in class regulatory and compliance solutions", continued Mr. Sanchez.

 

About Pharma-Bio Serv, Inc.

 

Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

 

 
1

 

 

Forward-Looking Statements

 

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2020, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

 

Company Contact:

 

Pedro J. Lasanta
Chief Financial Officer
787 278 2709

 

SOURCE: Pharma-Bio Serv, Inc.

 

 
2

 

EX-101.SCH 3 pbsv-20210914.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 pbsv-20210914_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 5 pbsv-20210914_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 pbsv-20210914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Entity Incorporation State Country Code Entity File Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address Country Entity Address Postal Zip Code City Area Code Local Phone Number EX-101.PRE 7 pbsv-20210914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 pbsv_8k_htm.xml IDEA: XBRL DOCUMENT 0001304161 2021-09-14 2021-09-14 iso4217:USD shares iso4217:USD shares 0001304161 false 8-K 2021-09-14 Pharma-Bio Serv, Inc. DE 0-50956 20-0653570 6 Road 696 Dorado PR 00646 787 278-2709 false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Sep. 14, 2021
Cover [Abstract]  
Entity Registrant Name Pharma-Bio Serv, Inc.
Entity Central Index Key 0001304161
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Sep. 14, 2021
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Incorporation State Country Code DE
Entity File Number 0-50956
Entity Tax Identification Number 20-0653570
Entity Address Address Line 1 6 Road 696
Entity Address City Or Town Dorado
Entity Address Country PR
Entity Address Postal Zip Code 00646
City Area Code 787
Local Phone Number 278-2709
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://pbsv.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pbsv_8k.htm pbsv-20210914.xsd pbsv-20210914_cal.xml pbsv-20210914_def.xml pbsv-20210914_lab.xml pbsv-20210914_pre.xml pbsv_ex991.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pbsv_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "pbsv-20210914_cal.xml" ] }, "definitionLink": { "local": [ "pbsv-20210914_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "pbsv_8k.htm" ] }, "labelLink": { "local": [ "pbsv-20210914_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "pbsv-20210914_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "pbsv-20210914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 20, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pbsv", "nsuri": "http://pbsv.com/20210914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "pbsv_8k.htm", "contextRef": "From2021-09-14to2021-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://pbsv.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "pbsv_8k.htm", "contextRef": "From2021-09-14to2021-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://pbsv.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001654954-21-010086-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-21-010086-xbrl.zip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